Quote | Metacrine Inc. (NASDAQ:MTCR)
Last: | $0.4949 |
---|---|
Change Percent: | 1.52% |
Open: | $0.4875 |
Close: | $0.4949 |
High: | $0.4974 |
Low: | $0.481 |
Volume: | 607,103 |
Last Trade Date Time: | 02/08/2023 03:41:02 pm |
News | Metacrine Inc. (NASDAQ:MTCR)
Nasdaq said Wednesday it will delist shares of Waitr ( OTCQB:ASAP ), Calithera Biosciences ( OTC:CALA ), Statera Biopharma ( OTCPK:STAB ), Allied Healthcare Products ( OTC:AHPI ) and Tricida ( OTCPK:TCDAQ ). The exchange will also delist Eqonex ( OTCPK:EQOSQ ), Sco...
A Beginner’s Guide to Trading Penny Stocks Under $1 The stock market is a complex and ever-changing landscape. For investors looking to get in on the action, stocks trading for under $1 can present significant potential returns. But like anything else in the stock market today, there...
Message Board Posts | Metacrine Inc. (NASDAQ:MTCR)
Subject | By | Source | When |
---|---|---|---|
$MTCR delisted from the Nasdaq to the OTC: | Renee | investorshub | 02/09/2023 12:03:30 AM |
Insider buying and a buyout may be already | HoldEm777 | investorshub | 12/03/2022 8:42:00 PM |
Double down | CrispCris | investorshub | 05/22/2022 2:07:01 PM |
50% workforce reduction in R&D: | DewDiligence | investorshub | 02/11/2022 2:47:01 PM |
you sure hit the nail on the head | pitacorp | investorshub | 02/05/2022 2:26:19 AM |
News, Short Squeeze, Breakout and More Instantly...
Metacrine Inc. Company Name:
MTCR Stock Symbol:
NASDAQ Market:
A Beginner’s Guide to Trading Penny Stocks Under $1 The stock market is a complex and ever-changing landscape. For investors looking to get in on the action, stocks trading for under $1 can present significant potential returns. But like anything else in the stock market today, there...
LA JOLLA, Calif., Dec. 23, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR) and Equillium, Inc. today announced the mutual termination of their previously announced definitive merger agreement. Metacrine is continuing to evaluate all strategic opportunities. Additional information reg...
SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company developing differentiated therapies for patients with gastrointestinal diseases, today reported its third-quarter 2022 financial results. “We made great progre...